Drug intelligence / Profile preview

Lu AF99722

Development stage: Unknown
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

Lu AF99722 is a radiolabeled version of the investigational drug Lu AF88434, developed by H. Lundbeck A/S. It is formulated as an oral solution and is utilized in clinical trials primarily to investigate the pharmacokinetic and metabolic properties of its parent compound, Lu AF88434, by tracing its movement and transformation within the body.

Other names: [14C]-radiolabelled Lu AF88434Lu AF99722 14C spiked dosage

Beyond the preview

Go deeper on Lu AF99722.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AF99722.

Explore the full profile